Evaluation of three commercially available rapid assays for detection of IgG and/or IGM antibodies to SARS-CoV-2 (COVID-19) for assessment of contact persons’ immune status and termination of quarantine and self-isolation – a prospective pilot study

Evaluation of three commercially available rapid assays for detection of IgG and/or IGM antibodies to SARS-CoV-2 (COVID-19) for assessment of contact persons’ immune status and termination of quarantine and self-isolation – a prospective pilot study - SARS-CoV-2 PoC/ELISA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00022083

Enrollment

Registered

2020-06-09

Start date

2020-05-20

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: participants with unknown Covid19 disease state Group 2: participants with known Covid19 disease state

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All employees of the university hospital Krems with age >18 years, and with a history of direct contact to a COVID-19 patient without full personal protective equipment may be included. Written consent to participate in the study is mandatory.

Exclusion criteria

Exclusion criteria: absence of consent; age <18 years; inadequate language skills for study information

Design outcomes

Primary

Measure	Time frame
Sensitivity and specificity of 3 commercially available SARS-CoV-2 antibody tests against the golden standard (ELISA)	—

Secondary

Measure	Time frame
Evaluation of the immunologic Covid19 disease state of the participants	—

Countries

Austria

Contacts

Public ContactKlaus Hackner

Universitsäsklinikum Krems

klaus.hackner@krems.lknoe.at+43273290044368

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026